Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

Overexpression miR-542-5p pristimerin treatment inhibits USP17L2. 1 / 1

| 1

➶

eidos

"Our results revealed that overexpression miR-542-5p with pristimerin treatment elevate AGO2 and reduce DUB3 expression significantly ( Figure 4G and H ) , therefore pristimerin and miR-542-5p overexpression had profoundly the same effect to inhibit breast cancer cells proliferation ."

32753899

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...